Kann man von Bauchspeicheldrüsenkrebs geheilt werden?

Inhaltsverzeichnis Show

Wie hoch sind die Heilungschancen bei Bauchspeicheldrüsenkrebs?
Wie kann man Bauchspeicheldrüsenkrebs besiegen?
Hat schon mal jemand Bauchspeicheldrüsenkrebs überlebt?
Kann man Bauchspeicheldrüsenkrebs mit Chemo heilen?

1. Krebs in Deutschland, Krebsregister: 5. �berarbeitete, aktualisierte Ausgabe. Saarbr�cken: Robert Koch-Institut und GEKID 2006; 36�8. 2. Michand de Gonzalez A, Sweetland S, Spencer E: A meta-analysis of obesity and risk of pancreatic cancer. JAMA 2001; 286: 921�9. 3. Muscat J, Stellman S, Hoffmann D, Wynder EL: Smoking and pancreatic cancer in men and women. Cancer Epidemiology, Biomarkers and Prevention 1997; 6: 15�9. MEDLINE 4. Lowenfels AP et al.: Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993; 328: 1433�7. MEDLINE 5. Greenhalf W, Neoptolemos J: Familial pancreatic cancer. In: Beger HG et al. eds: The Pancreas.Oxford: Blackwell Publisher 2008 (in press). 6. Whitcomb D: Hereditary chronic pancreatitis. The Pancreas 2e, Eds. Beger HG, et al. Oxford: Blackwell Publisher, 2008 (in press). 7. Beger HG, Schlosser W, Friess HM, B�chler MW: Duodenum-preserving head resection in chronic pancreatitis changes the natural course of the disease: a single-center 26-year experience. Ann Surg 1999; 230: 512�9. MEDLINE 8. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C et al.: International consensus guidelines for mangement of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatol 2006; 6: 17�32. MEDLINE 9. Gudjonsson B: Survival statistics gone awry. pancreatic cancer, a case in point. J Clin Gastroenterol 2002; 35: 180�4. MEDLINE 10. Hermanek P: Staging of exocrine pancreatic carcinoma. Eur J Surg Oncol 1991; 17: 167�72. MEDLINE 11. Takahashi T, Ishikara H, Kato H et al.: Intra-pancreatic, extratumoral perineural invasion. Acta Pathol Jpn 1992; 42: 99�103. 12. Wittekind Ch, Meyer HJ, Baetz E (eds.): TNM-Klassifikation maligner Tumoren (International Union against Cancer-UICC) Berlin, Heidelberg, New York: Springer Verlag 2003; 86�8. 13. Inoue S, Nakao A, Kasai Y et al.: Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/restriction fragment length polymorphism analysis. Jpn. J Cancer Res 1995; 86: 626�30. MEDLINE 14. Wolfrum F, Vogel I, F�ndrich F, Kalthoff H: Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. LAS 2005; 390: 430�41. MEDLINE 15. Okusaka T, Okada S, Ueno H et al.: Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas 2001; 22: 279�84. MEDLINE 16. Wintersperger BJ, Nikolaou K, Becker CR: Multidetector-row CT angiography of the aorta and visceral arteries. Semin Ultrasound CT MR 2004; 25: 25�40. MEDLINE 17. Richard KR, Semelka RC, Hyslop WB et al.: Suspected pancreatic cancer: evaluation by dynamic gadolinium enhanced 3-D-gradientecho-MRI. AJR Am J Roentgenol 2005; 185: 700�3. MEDLINE 18. Jimenez RE, Warshaw AL, Rattner DW, Willett CG, McGnath D, Fernandez-del Castillo C: Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000; 135: 409�14. MEDLINE 19. Adler G, Seufferlein T, Bischoff SC et al.: S3-Leitlinien �Exokrines Pankreaskarzinom� 2007. Ergebnis einer evidenzbasierten Konsensuskonferenz. Gastroenterologie 2007; 6: 487�523. MEDLINE 20. Oettle H, Post S, Neuhaus P, Gelldorf K et al.: Adjuvant chemotherapy with Genzitakine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 2007; 297: 267�77. MEDLINE 21. Selvia R, Fernandez-del Castillo C, Bassi C, Thayer SP et al.: Main-duct intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2004; 239: 678�87. MEDLINE 22. Shoup M, Conlon K, Klimstra D, Brennan MF: Is extended resection for adenocarcinoma of the body and tail of the pancreas justified? J Gastrointest Surg 2003; 7: 946�52. MEDLINE 23. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R: Surgery for exocrine pancreatic cancer � who are the 5- and 10-year-survivors? Oncology 1995; 52: 353�9. MEDLINE 24. Beger HG, Rau B, Gansauge F, Poch B, Link KH: Treatment of pancreatic cancer: challenge of facts. World J Surg 2003; 27: 1075�84. MEDLINE 25. Neoptolemos JP, Stocken DD, Friess H et al.: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350; 1200�10. MEDLINE e1. Hermanek P: Staging of exocrine pancreatic carcinoma. Eur J Surg Oncol 1991; 17: 167�72. MEDLINE e2. Takahashi T, Ishikara H, Kato H et al.: Intra-pancreatic, extratumoral perineural invasion. Acta Pathol Jpn 1992; 42: 99�103. e3. Bockman DE, B�chler MW, Beger HG: Interaction of pancreatic ductal carcinoma with nerves leads to nerve damage. Gastroenterology 1994; 107: 219�30. MEDLINE e4. Ohigashi H, Ishikawa O, Sasaki Y et al.: K-ras point mutation in the nerve plexus around superior mesenteric artery in resectable adenocarcinoma of the pancreatic head. Arch Surg 2000; 135: 1450�5. MEDLINE e5. Inoue S, Nakao A, Kasai Y et al.: Detection of hepatic micrometastasis in pancreatic adenocarcinoma patients by two-stage polymerase chain reaction/ restriction fragment length polymorphism analysis. Jpn J Cancer Res 1995; 86: 626�30. MEDLINE e6. Wolfrum F, Vogel I, F�ndrich F, Kalthoff H: Detection and clinical implications of minimal residual disease in gastro-intestinal cancer. LAS 2005; 390: 430�41. MEDLINE e7. Heeckt P, Safi F, Binder T et al.: Free intraperitoneal tumor cells in pancreatic cancer � significance for clinical course and therapy. Chirurgie 1992; 78: 2485. MEDLINE e8. Tsuchiya R, Oribe T, Noda T: Size of the tumor and other factors influencing prognosis of carcinoma of the head of the pancreas. Am J Gastroenterol 1985; 80: 459. MEDLINE e9. Cameron JL, Crist DW, Sitzmann JV et al.: Factors influencing survival after pancreatico-duodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120. MEDLINE e10. Nagakawa T, Kayahara M, Ohta T et al.: Patterns of neural and plexus extensive invasion of human pancreatic cancer and experimental cancer. Int J Pancreatol 1991; 10: 113. MEDLINE e11. Ishikawa O: Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Hepatogastroenterology 1996; 43: 320. MEDLINE e12. Geer RJ, Brennan MF: Prognostic indicators for survival after resection of adenocarcinoma of the pancreas. Am J Surg 1993; 165: 68. MEDLINE e13. Yeo C, Abrams R, Grochow L et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann Surg 1997; 225: 621. MEDLINE e14. Kleeff J, Michalski C, Friess H, B�chler MW: Pancreatic cancer. from bench to 5-year-survival. Pancreas 2006; 33: 111�8. MEDLINE e15. Ando N, Nakao A, Nomoto S et al.: Detection of mutant K-ras in dissected paraaortic lymph nodes of patients with pancreatic adenocarcinoma. Pancreas 1997; 15: 374�8. MEDLINE e16. Hosch SB, Knoefel WT, Metz S et al.: Early lymphatic tumor cell dissemination in pancreatic cancer: frequency and prognostic significance. Pancreas 1997; 15: 154�9. MEDLINE e17. E Tamagawa, M Ueda, S Takahashi et al.: Pancreatic lymph nodal and plexus micrometastases detected by enriched polymerase chain reaction and nonradioisotopic single-strand conformation polymorphism analysis: a new predictive factor for recurrent pancreatic carcinoma. Clin Cancer Res 1997; 3: 2143�9. e18. Demuere MJ, Doffek KM, Komoiowski RA et al.: Adenocarcinoma of the pancreas. detection of occult metastases in regional lymph nodes by PCR-based assay. Cancer 1998; 83: 1328�34. e19. Brown HM, Ahrendt SA, Komorowski RA, Doffek KM, Wilson SD, Demeure MJ: Immunhistochemistry and molecular detection of nodal micrometastases in pancreatic cancer. J Surg Res 2001; 95: 141�6. MEDLINE e20. Niedergethmann M, Rexin M, Hildenbrand R et al.: Prognostic implications of routine, immunohistochemical and molecular staging in resectable pancreatic adenocarcinoma. Am J Surg Pathol 2002; 26: 1578�87. MEDLINE e21. Kanemitsu K, Hiraoka T, Tsuji T, Inoue K, Takamori H: Implication of micrometastases of lymph nodes in patients with extended operation for pancreatic cancer. Pancreas 2003; 26: 315�21. MEDLINE e22. Okusaka T, Okada S, Ueno H et al.: Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas 2001; 22: 279�84. MEDLINE e23. Hirai I, Kimura W, Ozawa K et al.: Perineural invasion in pancreatic cancer. Pancreas 2002; 24: 15�25. MEDLINE e24. Pour PM, Egami H, Takiyama Y: Patterns of growth and metastases of induced pancreatic cancer in relation to the prognosis and its clinical implications. Gastroenterology 1991; 100: 529�36. MEDLINE e25. Kayahara M, Nagakawa T, Konishi I et al.: Clinicopathological study of pancreatic carcinoma with particular reference to the invasion of the extrapancreatic neural plexus. Int J Pancreatol 1991; 10: 105�11. MEDLINE e26. Nagakawa T, Kayahara M, Ueno K et al.: A clinicopathologic study on neural invasion in cancer of the pancreatic head. Cancer 1992; 69: 930�5. MEDLINE e27. Nakao A, Harada A, Nonami T et al.: Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996; 12: 357�61. MEDLINE e28. Dang C, Zhang Y, Ma Q, Shimahara Y: Expression of nerve growth factor receptor is correlated with progression and prognosis of human pancreatic cancer. J Gastroenterol Hepatol 2006; 21: 850�8. MEDLINE e29. Okada Y, Eibl G, Duffy JP et al.: Glial cell-derived neurotrophic factor upregulates the expression and activation of matrix metalloproteinase-9 in human pancreatic cancer. Surgery 2003; 134: 293�9. MEDLINE e30. Horton KM, Fishman EK: Adenocarcinoma of the pancreas: CT imaging. Radiol Clin North Am 2002; 40: 1263�72. MEDLINE e31. Wintersperger BJ, Nikolaou K, Becker CR: Multidetector-row-CT-angiography of the aorta and visceral arteries. Semin Ultrasound CT MR 2004; 25: 25�40. MEDLINE e32. Richard KR, Semelka RC, Hyslop WB et al.: Suspected pancreatic cancer: evaluation by dynamic gadolinium enhanced 3-D-gradientecho MRI. AJR Am J Roentgenol 2005; 185: 700�3. MEDLINE e33. Chicoskie C, Tello R: Gadolinium-enhanced MDCT-angiography of the abdomen: feasibility and limitations. Am J Roentgenol 2005; 184: 1821�8. MEDLINE e34. Su D, Yamaguchi K, Tanaka M: The characteristics of disseminated tumor cells in pancreatic cancer: a black box needs to be explored. Pancreatology 2005; 5: 316�24. MEDLINE e35. Schembre D:The role of EUS for diagnosis and differential diagnosis of neoplastic lesions. In: Beger HG et al. eds.: The Pancreas. Oxford: Blackwell Publisher 2008 (in press). e36. Shoup M, Winston C, Brennan MF, Bassman D, Conlon KC: Is there a role for staging laparoscopy in patients with locally advanced, unresectable pancreatic adenocarcinoma? Laparoscopy Pancr Cancer 2004; 8: 1068�71. MEDLINE e37. Klapmann JB, Logrono R, Dye CE, Waxman I: Clinical impact of on-site cytopathology interpretation on endoscopic US-guided fine needle aspiration. Am J Gastroenterol 2003; 98: 1289�94. MEDLINE e38. Imamura M, Doi R: Treatment of locally advanced pancreatic cancer. Should we resect when resectable? Pancreas 2004; 28: 293�5. MEDLINE e39. Lillemoe KD, Cameron JL, Yeo CJ et al.: Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996; 223: 718�28. MEDLINE e40. Suzuki Y, Atomi Y, Sugiyama M et al.: Japanese multiinstitutional study of intraductal papillary mucinous cystic tumor. Pancreas 2004; 28: 241�6. MEDLINE e41. Sohn TA, Yeo CJ, Cameron JL, Hinhan RH, Fukushima N, Campbell KA et al.: Introductal papillary mucinous neoplasms of the pancreas: an update experience. Ann Surg 2004; 239: 788�97. MEDLINE e42.Gordon TA, Burleyson G, Tielsch JM et al.: The effects of regionalization on cost and outcome for one high-risk general surgical procedure. Ann Surg 1995; 221: 43�9. MEDLINE e43.Liebermann MD, Killborn H, Lindsey M et al.: Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995; 222: 638�45. MEDLINE e44. Gouma DJ, van Geenen RCI, van Gulik THM: Rates of complications and death after pancreatico-duodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000; 232: 786�94. MEDLINE e45. Bramhall SR, Allum WH, Jones AG et al.: Treatments and survival in 13 560 patients with pancreatic cancer and incidence of the disease in the West Midlands: an epidemiological study. Br J Surg 1995; 82: 111�5. MEDLINE e46. Neoptolemos JP, Russel RCG, Bramhale S, et al.: Low mortality following resection for pancreatic and periampullary tumors in 1 026 patients. Br J Surg 1997; 84: 1370. MEDLINE e47. Gordon TA, Bowman HM, Bass EB et al.: Complex gastrointestinal surgery: impact of provider experience on clinical and economic outcomes. J Am Coll Surg 1999; 189: 46�56. MEDLINE e48. Scand J: Finnish Surg Society Annual Meeting. 1996: 17�45. e49. Birkmeyer JD, Finlayson SRG, Tosteson ANA et al.: Effect of hospital volume on in-hospital mortality with pancreatico-duodenectomy. Surgery 1999; 125: 250�6. e50. Yeo CJ, Cameron JL, Lillemoe KD et al.: Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221: 721�31. MEDLINE e51. Christein JD, Kendrick M, Iqbal C, Nagorney D, Farnell M: Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9: 922�7. MEDLINE e52. Millikan KW, Deziel DJ, Silverstein JC et al.: Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 1999; 65: 618�23. MEDLINE e53. Sohn T, Yeo CJ, Cameron JL et al.: Resected adenocarcinoma of the pancreas � 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567�79. MEDLINE e54. Benassi G, Mastrorilli M, Quarto G et al.: Survival after pancreatico-duodenectomy for ductal adenocarcinoma of the head of the pancreas. Chir Ital 2000; 52: 263�70. e55. Neoptolemos JP, Stocken DD, Dunn JA et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234: 758�68. MEDLINE e56. Raut CP, Tseng JF, Sun CC et al.: Impact of resection status on patterns of failure and survival after pancreatico-duodenectomy for pancreatic adenocarcinoma. Br J Surg 2008; in press. e57. Pedrazzoli S, DiCarlo V, Dionigi R et al.: Standard versus extended lymphadenectomy associated with pancreatico-duodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective randomized study. Ann Surg 1998; 228: 508�17. MEDLINE e58. Yeo CJ, Cameron JL, Lillemoe KD et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity and mortality. Ann Surg 2002; 236: 355�66, discussion 366�8. MEDLINE e59. Farnell MB, Pearson RK, Sarr MG et al.: A prospective randomized trial comparing standard pancreatico-duodenectomy with pancreaticoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138: 618�28. MEDLINE e60. Nimura Y: EHPBA congress abstract 2005. e61. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006�10. MEDLINE e62. Yeo C. Abrams R, Grochow L, Sohn T, Ord S, Gruban R et al.: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. Ann Surg 1997; 225: 621�36. MEDLINE e63. Klinkenbigl JH, Jeekel H, Sahmond T: Adjuvant radiotherapy and 5-Fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase-III-trial of the EORTC gastrointestinal tract cancer cooperative group. Am Surg 1999; 230: 776�84. MEDLINE e64. Picozzi VJ, Kozarek RA, Traverso L: Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185: 476�80. MEDLINE e65. Regine WF, Winter KW, Abrams R et al.: RTOG 9704 a phase-III-study of adjuvant pre- and post-chemoradiation (CRT) 5-Fu vs. Gemcitabine for resected pancreatic adenocarcinoma. J Clin Oncol 2006; suppl 185: 4007. e66. Hecht SS: Cigarette smoking: cancer risks, carcinogens and mechanisms. Langenbecks Arch Surg 2006; 391: 603�13. MEDLINE e67. Lowenfels AB, Maisonneuve P, Withcomb DC et al.: Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA 2001; 286: 169�70. MEDLINE e68. Beger HG, Rau BM, Siech M, Schwarz M, Poch B: Duodenum-preserving pancreatic head resection for cystic neoplastic head lesions. HBP-Surgery 2008, in press. e69. Heinemann V, Wilkowski R: Behandlung des fortgeschrittenen und metastasierten Pankreaskarzinoms. Dtsch Arztebl 2005; 102(40): A 2720�5. VOLLTEXT e70. McFaul CD, Greenhalf W, Earl J et al.: Anticipation in familial pancreatic cancer. Gut 2006; 55: 252�8. MEDLINE

Wie hoch sind die Heilungschancen bei Bauchspeicheldrüsenkrebs?

Die Heilungschancen sind bei Bauchspeicheldrüsenkrebs noch immer gering, nur etwa 10% aller Patienten und Patientinnen sind fünf Jahre nach Erstdiagnose noch am Leben. Günstig für die Prognose ist es, Bauchspeicheldrüsenkrebs frühzeitig zu erkennen.

Wie kann man Bauchspeicheldrüsenkrebs besiegen?

Pankreaskrebs – Ist Heilung möglich? Die Überlebenschancen werden bei Pankreaskrebs nicht sehr hoch eingeschätzt. Es sei ein besonders aggressiver Krebs, heisst es. Als einzige Behandlungsmethode kommen in der Schulmedizin daher auch aggressivste Chemotherapien zum Einsatz.

Hat schon mal jemand Bauchspeicheldrüsenkrebs überlebt?

Fortschritte in der Therapie des Bauchspeicheldrüsenkrebs Werner Müller und Albert Meier – zwei schwerkranke Menschen, die überlebt haben und deren Geschichten auch anderen Betroffenen Mut machen sollen. Zumal sich die Medizin seit ihrer Diagnose vor vielen Jahren längst weiterentwickelt hat.

Kann man Bauchspeicheldrüsenkrebs mit Chemo heilen?

Eine Heilung des Bauchspeicheldrüsenkarzinoms allein durch die Gabe von Zytostatika ist nicht möglich. In manchen Fällen, bei lokal fortgeschrittenen Pankreaskarzinomen, kann der Arzt erwägen, eine Chemotherapie vor der Operation zu verabreichen.